A Phase II Open Label Single-Arm Study of E7389 [eribulin] in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease.

Trial Profile

A Phase II Open Label Single-Arm Study of E7389 [eribulin] in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 14 May 2012 Additional lead trial centre and investigator (Dale Shuster) identified as reported by ClinicalTrials.gov.
    • 14 May 2012 Company (Eisai Inc.) added to the associations field as reported by ClinicalTrials.gov.
    • 17 May 2011 Results from this study were used to support approval of Eribulin in Switzerland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top